Keyword Analysis & Research: pfizer news


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
pfizer news0.790.591528911
pfizer1.460.23689776
news1.790.33200984

Keyword Research: People who searched pfizer news also searched

Keyword CPC PCC Volume Score
pfizer news1.970.1562412
pfizer news today1.990.3778280
pfizer newsroom0.50.1439411
pfizer news release0.980.749628
pfizer news headlines1.941310541
pfizer news stock0.860.73673
pfizer newsletter0.660.7786410
pfizer news layoffs1.20.9599953
pfizer news stories1.670.4156977
pfizer news uk0.580.558087
pfizer news kent0.891395843
pfizer news youtube1.780.4156033
pfizer news articles1.740.843888
pfizer news for the vaccinated1.580.5323512
pfizer vaccine news0.070.1647771
pfizer latest news0.350.179378
pfizer covid vaccine news1.140.660521
what is the new pfizer vaccine called0.340.7890540
breaking news on pfizer stock1.070.110789
when will the new pfizer booster be available0.490.7942884

Search Results related to pfizer news on Search Engine

  • Newsroom | Pfizer

    pfizer.com

    https://www.pfizer.com/newsroom

    WebThe latest news from Pfizer and its strategic partners 02.12.2024 Corporate Partnerships UT Southwestern collaborates with Pfizer to develop improved RNA Delivery Technologies 12.05.2023 Corporate Partnerships Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to ...

    DA: 68 PA: 64 MOZ Rank: 95

  • Pfizer Announces Positive Top-Line Results from Phase 3 Study …

    pfizer.com

    https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-1

    WebApr 9, 2024 · ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk. The vaccine was well-tolerated and demonstrated an immune response non-inferior to adults aged 60 years and older Pfizer intends to submit these findings to regulatory agencies to seek approval of ABRYSVO in …

    DA: 89 PA: 58 MOZ Rank: 15

  • Press Releases | Pfizer

    pfizer.com

    https://www.pfizer.com/newsroom/press-releases

    WebApr 11, 2024 · Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/ Refractory Diffuse Large B-cell Lymphoma (DLBCL) 03.05.2024.

    DA: 75 PA: 11 MOZ Rank: 34

  • Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives …

    pfizer.com

    https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-comirnatyr-receives-full

    WebDec 11, 2020 · COMIRNATY is the first COVID-19 vaccine to be granted approval by the FDA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005499/en/ The vaccine has been available in the U.S. under Emergency Use Authorization (EUA) since December 11, …

    DA: 21 PA: 9 MOZ Rank: 65

  • Pfizer stays the course on 2024 outlook after delivering better

    apnews.com

    https://apnews.com/article/pfizer-fourth-quarter-covid-556c0206d24ada6d2ac8581f5100b1fc

    WebPfizer turned in a better-than-expected fourth quarter, boosted by products outside the drugmaker’s slumping COVID-19 vaccine and treatment. The New York drugmaker also said Tuesday it’s reaffirming its forecast for 2024, a month after surprising Wall Street with an initial outlook that missed consensus.

    DA: 50 PA: 93 MOZ Rank: 78

  • Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 …

    pfizer.com

    https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine

    WebNov 18, 2020 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the …

    DA: 26 PA: 33 MOZ Rank: 60

  • Pfizer and BioNTech Announce Omicron-Adapted COVID-19 …

    pfizer.com

    https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-omicron-adapted-covid-19

    WebSaturday, June 25, 2022 - 10:00am. View pdf copy Copy to clipboard Open in tab. Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase ...

    DA: 89 PA: 6 MOZ Rank: 40

  • Pfizer and BioNTech Announce Phase 3 Trial Data Showing High …

    pfizer.com

    https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-phase-3-trial-data-showing

    WebSep 22, 2021 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 years of age …

    DA: 12 PA: 16 MOZ Rank: 25

  • Pfizer and BioNTech Announce Vaccine Candidate Against …

    pfizer.com

    https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against

    WebNov 9, 2020 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the …

    DA: 25 PA: 71 MOZ Rank: 68

  • Pfizer’s vaccine: Here’s what we know | CNN

    cnn.com

    https://edition.cnn.com/2020/12/11/health/pfizer-vaccine-what-we-know/index.html

    WebDec 11, 2020 · Here’s what we know about the Pfizer/BioNTech Covid-19 vaccine. Ad Feedback. Who will get it first? Now that CDC Director Dr. Robert Redfield has accepted the ACIP’s recommendation,...

    DA: 9 PA: 56 MOZ Rank: 77